Posts Tagged ‘Endocrine Society’

Semaglutide in JAMA Again: Maintaining a Benefit

March 24, 2021 — If you had any doubt about prior reports that semaglutide is likely to be a “game changer” for obesity care, perhaps you should look at JAMA today. Just one month after another paper in JAMA, semaglutide is back in the journal. This time, it is a 68-week study that shows the value of maintaining therapy […]

News from The Endocrine Society on Oral Semaglutide

March 26, 2019 — If you talk to researchers and clinicians deeply involved in the future of obesity treatment, you will find quite a buzz about a type 2 diabetes drug called semaglutide. It’s a cousin of the most successful new drug for treating obesity – liraglutide. Right now, both of these drugs are sold only as an injection. […]

The Endocrine Society: Honestly Seeking Answers About Obesity

June 28, 2017 — Obesity rates started soaring almost four decades ago. Multiple presidents and surgeons general have called for action to address it. You might think we would have an answer by now to the most basic question: why? But we don’t. And this week, the Endocrine Society presented the facts in a scientific statement. It calls for […]

Strong Evidence Links Chemical Exposure to Obesity

September 30, 2015 — You can be forgiven for believing that the global epidemic of obesity is simply a “preventable” problem caused by unhealthy behaviors of “dietary patterns and physical activity.” The World Health Organization, CDC, and innumerable other authorities have repeated this supposition enough so that it has assumed the status of a fact. Thus, the notion that chemical exposure […]

New Guidance on Obesity Drugs

January 17, 2015 — Drugs can have a profound effect on the health of people with obesity — for better or for worse. When the long process to develop new obesity treatment guidelines in 2013 did not include anything about drugs, a sigh of disappointment was audible. So the brand new publication of guidance on obesity drugs by the […]